Search results (655)
« Back to PublicationsAntibody-Drug Conjugates Synergize with Agonist Anti-CD137 Monoclonal Antibodies in Solid Tumors.
Gomis G. et al, (2026), Cancer research
Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.
Helgadottir H. et al, (2026), Clinical cancer research : an official journal of the American Association for Cancer Research
Long-term follow-up of a phase 1/2 trial of anti-GDF-15 antibody visugromab plus anti-PD-1 antibody nivolumab in anti-PD-1/-L1 relapsed/refractory solid tumors.
Melero I. et al, (2026), Journal of hematology & oncology
Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies.
Sweis RF. et al, (2026), Journal for immunotherapy of cancer, 14
A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.
Garralda E. et al, (2026), Clinical cancer research : an official journal of the American Association for Cancer Research, 32, 2556 - 2571
Cross-priming underlies the efficacy of antibody-drug conjugates and immunotherapy combinations.
Gomis G. et al, (2026), Trends in immunology
Engineering and improving anti-CTLA-4 checkpoint inhibitors.
Galvez-Cancino F. et al, (2026), Clinical cancer research : an official journal of the American Association for Cancer Research
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.
Rohrberg KS. et al, (2026), Journal for immunotherapy of cancer, 14
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.
Melero I. et al, (2026), Nature medicine
Intratumoral heterogeneity and immunotherapy resistance: clinical implications.
Keenan BP. et al, (2026), Annals of oncology : official journal of the European Society for Medical Oncology, 37, 314 - 328
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.
Beernaert B. et al, (2026), Science advances, 12
Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.
Sanmamed MF. et al, (2026), Clinical cancer research : an official journal of the American Association for Cancer Research, 32, 1036 - 1045